Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.69 USD

1.69
2,961,327

+0.08 (4.97%)

Updated Oct 4, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%

by Zacks Equity Research

Lexicon (LXRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally

by Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.

Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

by Zacks Equity Research

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -144.44% and -60.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -31.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

by Zacks Equity Research

Key highlights of the past week are multiple study failures and other pipeline updates.

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

by Zacks Equity Research

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

by Zacks Equity Research

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 42.86% and 24.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Lexicon Pharmaceuticals (LXRX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

Zacks.com featured highlights include: Lexicon, Medtronic and NetApp

by Zacks Equity Research

Zacks.com featured highlights include: Lexicon, Medtronic and NetApp

Tirthankar Chakraborty headshot

3 Stocks That Flaunt Solid Earnings Acceleration

by Tirthankar Chakraborty

Studies show that majority of successful stocks see acceleration in earnings before a positive stock price movement.

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and -48.16%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 5.71% and -17.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Lexicon (LXRX) Looks Good: Stock Adds 7.6% in Session

    by Zacks Equity Research

    Lexicon (LXRX) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.

      Company News for June 12, 2017

      by Zacks Equity Research

      Companies in the News are: DFT,DLR,ENDP,P,SIRI,LXRX

        Surging Earnings Estimates Signal Good News for Lexicon (LXRX)

        by Zacks Equity Research

        Lexicon (LXRX) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision.

          Arpita Dutt headshot

          4 FDA Decisions to Watch Out for in Feb 2017

          by Arpita Dutt

          So far this year, the FDA has approved one drug. Will the pace of drug approvals pick up in February?